SCHEMBL4879185

SCHEMBL4879185

CCOC(=O)C(C)Oc1ccc(Cl)cc1C1CCCCC1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 9/20 0.74
PTGDR Q13258 5/20 0.74
PTGER2 P43116 1/20 0.56
MAPT P10636 2/20 0.50
PPOX P50336 2/20 0.47
PPARG P37231 1/20 0.46
PPARD Q03181 1/20 0.46
PPARA Q07869 1/20 0.46
TSHR P16473 1/20 0.44
HTR2A P28223 1/20 0.44
HTR2C P28335 1/20 0.44
HTR2B P41595 1/20 0.44
HPGD P15428 2/20 0.43
GAA P10253 1/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
LMNA P02545 1/20 0.43
ALOX12 P18054 1/20 0.43
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4885231 0.86 PTGDR2 (0.56) PTGDR2PTGDRMAPTPPOXTSHR
SCHEMBL4877330 0.85 PTGDR2 (1.00) PTGDR2PTGDRPTGER2MAPTPPARG
SCHEMBL21059478 0.81 PTGDR2 (0.92) PTGDR2PTGDRPTGER2MAPTPPARG
SCHEMBL21059480 0.81 PTGDR2 (0.92) PTGDR2PTGDRPTGER2MAPTPPARG
SCHEMBL4882287 0.80 PTGDR2 (0.78) PTGDR2PTGDRPTGER2HPGDALDH1A1
SCHEMBL21059475 0.78 PTGDR2 (0.87) PTGDR2PTGDRPTGER2MAPTPPARG
SCHEMBL21059473 0.78 PTGDR2 (0.87) PTGDR2PTGDRPTGER2MAPTPPARG
SCHEMBL10022853 0.78 SMN1; SMN2 (0.66) MAPTTSHRHTR2AHTR2CHTR2B
SCHEMBL11874266 0.78 TSHR (0.70) MAPTTSHRHTR2AHTR2CHTR2B
SCHEMBL21056076 0.78 TSHR (0.70) MAPTTSHRHTR2AHTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269335-A1 2-(4-Chloro-2-cyclohexylphenoxy)propionic acid; (4-Bromo-2-cyclohexylphenoxy)propionic acid ethyl ester; ethyl-2-bromopropionate is reacted with 4-chloro-2-cyclohexylphenol in presence of cesium carbonate and N,N-dimethylfomamide; antiallergenic and antiinflammatory agent NOVARTIS AG (CH) 2008-10-30 US disclosed
EP-1756032-A1 CRTH2 RECEPTOR ANTAGONISTS Novartis AG (CH) 2007-02-28 EP disclosed
WO-2005105727-A1 CRTH2 RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269335-A1 2-(4-Chloro-2-cyclohexylphenoxy)propionic acid; (4-Bromo-2-cyclohexylphenoxy)propionic acid ethyl ester; ethyl-2-bromopropionate is reacted with 4-chloro-2-cyclohexylphenol in presence of cesium carbonate and N,N-dimethylfomamide; antiallergenic and antiinflammatory agent EPX, NR3C2, FPR2 PTGDR2 245/4885PTGDR 151/4885PTGER2 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.